Heterogeneity and Plasticity of Immune Inflammatory Responses in the Tumor Microenvironment: Their Role in the Antitumor Effect and Tumor Aggressiveness


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

This review considers the role that immune inflammatory responses (IIRs) play in tumor development and progression. Intratumoral IIR heterogeneity is presumably due to simultaneous differentiation and activation of certain T helper (Th) subpopulations and macrophages in various loci of the tumor, their phenotypic plasticity, and their antagonism of Th1 and Th2 responses. Evidence is provided to demonstrate that the IIR type in the tumor microenvironment determines the probability of the epithelial–mesenchymal transition (EMT), the emergence of invasive properties in tumor cells, the formation of tumor and premetastatic niches, and chemosensitivity. It is hypothesized that the effect of IIRs on tumor cells depends on the IIR type, which determines the cell and cytokine spectrum in the tumor microenvironment, rather than on the efficiency of specific immune responses to tumor antigens. Lastly, it is assumed that more efficient targets for IIR guidance are not provided by single molecules, but rather by the signaling pathways that can permanently prevent the Th2-type IIRs or suppress inflammatory reactions in the tumor.

About the authors

V. M. Perelmuter

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050

L. A. Tashireva

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050

V. N. Manskikh

Department of Bioengineering and Bioinformatics, Moscow State University

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Moscow, 119991

E. V. Denisov

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Tomsk State University

Author for correspondence.
Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050; Tomsk, 634050

O. E. Savelieva

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Tomsk State University

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050; Tomsk, 634050

E. V. Kaygorodova

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050

M. V. Zavyalova

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Tomsk State University; Siberian State Medical University

Email: d_evgeniy@oncology.tomsk.ru
Russian Federation, Tomsk, 634050; Tomsk, 634050; Tomsk, 634050


Copyright (c) 2018 Pleiades Publishing, Ltd.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies